Salmeterol injection - Neothetics

Drug Profile

Salmeterol injection - Neothetics

Alternative Names: LIPO-202; Salmeterol xinafoate - Lithera; Salmeterol xinafoate - Neothetics

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lithera
  • Developer Neothetics
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Subcutaneous fat disorders

Most Recent Events

  • 08 Sep 2017 Salmeterol injection is still in phase III development for Subcutaneous fat disorders in USA (Neothetics pipeline, September 2017)
  • 05 Apr 2017 Neothetics has patent protection for salmeterol injection in USA
  • 23 Mar 2017 Neothetics terminates a phase III extension study in Subcutaneous fat disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top